Madecassoside is one of four active fractions inside Centella asiatica (cica). It is a triterpene saponin with the strongest anti-inflammatory and wound-healing evidence in the centella family. Most “cica” products contain centella asiatica extract — a blend where madecassoside concentration is unspecified and often low. The clinical effect depends entirely on which fraction the formulation actually delivers.
Centella asiatica has been used in traditional Indian and Southeast Asian medicine for over two thousand years. Modern dermatology research narrowed the active components down to four triterpene saponins: asiaticoside, madecassoside, asiatic acid, and madecassic acid. The four fractions have overlapping but distinct mechanisms. Madecassoside is the fraction with the strongest evidence for anti-inflammatory effect, the highest skin penetration at standard topical concentrations, and the cleanest safety profile across darker skin tones where centella is widely used post-procedure.
Most “cica” or “centella” products on the shelf don’t specify which fraction they contain. The marketing markup positions them all as equivalent. They’re not. A 1% madecassoside-isolated serum and a 1% “centella extract” cream may share the same INCI naming convention and deliver radically different clinical results.
The four centella fractions in 30 seconds
Madecassoside. Triterpene saponin. Strongest anti-inflammatory effect via downregulation of NF-κB pathway and reduction in pro-inflammatory cytokines (IL-1β, TNF-α). Best evidence for post-procedure recovery and rosacea adjacent presentations.
Asiaticoside. Also triterpene. Primary mechanism is collagen-synthesis upregulation via TGF-β signaling. Strongest evidence for wound healing and scar reduction. Slightly weaker anti-inflammatory profile than madecassoside.
Asiatic acid. The aglycone form (no sugar group). Higher lipophilicity gives it deeper penetration but typically lower formulation concentrations because of solubility constraints. Anti-inflammatory and antimicrobial.
Madecassic acid. The fourth fraction. The least-studied. Some evidence for antioxidant activity. Usually included in centella extracts but rarely positioned as a primary active.
The clinical evidence is unusually focused
For a botanical ingredient, centella has an unusually deep clinical evidence base in dermatology — the kind that’s normally reserved for pharmaceutical-grade actives. The relevant trials cluster around madecassoside specifically:
Bylka and colleagues (2013, Postepy Dermatol Alergol) reviewed centella in dermatologic applications and identified madecassoside as the primary effector across rosacea, atopic dermatitis, and post-procedure recovery indications. The mechanism work was further developed by Won and colleagues (2010, Phytotherapy Research) demonstrating direct NF-κB inhibition at 0.1-1% topical concentrations.
The pattern across studies: madecassoside-isolated formulations at 0.1-1% concentration produce measurable reductions in erythema, transepidermal water loss, and patient-reported irritation in compromised skin within 14 days of consistent use. Centella-extract formulations at unspecified madecassoside concentration produce more variable results, often clustering around the lower end of the expected response curve because the actual madecassoside content is below the therapeutic threshold.
Where the cica label gets messy
The marketing problem is the conflation of “centella asiatica extract” with “madecassoside.” The two are not interchangeable. Centella extract is a botanical preparation containing variable concentrations of all four fractions depending on the extraction method, plant source, and standardization. Madecassoside is a specific molecular fraction that can be isolated and dosed precisely.
A “cica cream” listing “centella asiatica extract” as the active may contain 0.01% madecassoside — well below the therapeutic threshold — and 5% centella extract by weight. The 5% number looks impressive on the front label; the actual therapeutic delivery is minimal.
A product listing “madecassoside 0.5%” or “madecassoside 1%” as a separate ingredient is delivering measurable therapeutic concentration. The price point usually reflects this — isolated madecassoside is expensive to produce and is generally found in dermatology-adjacent product lines (Avene, La Roche-Posay Cicaplast, Skinceuticals, A’pieu) rather than mass-market “cica” formulations.
Formulations that actually contain therapeutic madecassoside
SK-Influx Mela-Soothe (Korean derm market, ~$28): 1% isolated madecassoside, no added centella extract dilution. Clean formulation, fast-absorbing texture.
Dr. Jart+ Cicapair Tiger Grass Color Correcting Treatment, $52: Madecassoside listed in the higher inventory positions. The tint is a brand-positioning choice; the active mechanism is real.
Avene Cicalfate+ Restorative Protective Cream, $32: Madecassoside plus the brand’s thermal spring water base. European pharmacy standard for post-procedure recovery. The most-evidenced formulation for rosacea-adjacent presentations.
La Roche-Posay Cicaplast Baume B5, $18: Lower madecassoside concentration than the Avene option but the panthenol-rich base extends recovery support. Reasonable price point for daily use.
Purito Centella Green Level Recovery Cream, $14: Higher in centella extract than isolated madecassoside, but still contains a meaningful concentration. Good budget option for general centella exposure.
How to use madecassoside
For acute irritation (post-retinoid flare, post-procedure recovery, post-chemical-peel barrier compromise): apply 2-3 times daily for the first 7-10 days, then reduce to once daily as the underlying inflammation resolves. The recovery acceleration is most visible in the first 72 hours.
For chronic low-grade inflammation (rosacea-adjacent presentations, sensitive skin maintenance): once daily, evening application, layered after lighter actives and before the moisturizer layer. The cumulative effect builds over 4-6 weeks; intermittent use produces less consistent results.
For post-procedure prevention (day-of and following 14 days post-laser, post-peel, post-microneedling): 3x daily for the first 72 hours, 2x daily through day 7, 1x daily through day 14. This is the standard dermatology protocol for centella post-procedure use.
What mainstream coverage gets wrong
The dominant pattern in skincare media is treating all “centella” products as equivalent. The marketing reinforces this because differentiating by fraction would require disclosing the actual madecassoside concentration, which is rarely on the front label.
The second consistent error: pairing centella with retinoids in the same application step as a “recovery layer.” Madecassoside helps recover from retinoid irritation but applying both in the same session reduces madecassoside’s penetration and therapeutic effect. The right protocol is retinoid one night, madecassoside the next night, with the recovery layer happening on the alternating nights rather than the same night.
The third error: treating centella as a daily preventative for skin that isn’t compromised. Healthy skin doesn’t have the inflammatory drivers that madecassoside addresses. Daily application to healthy skin produces minimal benefit and occupies routine real estate that could go to more useful actives.
FAQ
Is madecassoside the same as centella asiatica? No. Centella asiatica is the plant. Madecassoside is one of four active fractions in the plant. A “centella extract” product contains variable concentrations of all four fractions; a “madecassoside” product contains the isolated active at a specified concentration.
How much madecassoside do I need in a product? 0.1-1% concentration of isolated madecassoside is the therapeutic range. Below 0.1%, the clinical effect is minimal. Above 1%, the marginal benefit per added concentration drops sharply.
Can I use madecassoside with retinoids? Yes, on alternating nights. Same-session layering reduces madecassoside penetration. Alternate-night sequencing produces the best results for retinoid-sensitive users.
Is madecassoside safe for darker skin tones? Yes. The anti-inflammatory mechanism is independent of melanocyte activity, and the irritation-PIH risk is essentially zero. It’s frequently the right post-procedure recovery active for Fitzpatrick IV-VI patients.
What’s the difference between “cica” and “madecassoside” on a product label? “Cica” is a marketing shorthand for centella-derived ingredients without specifying the active fraction. “Madecassoside” is a specific molecular fraction. Look for products listing madecassoside as a separate INCI entry, not just “centella asiatica extract.”
References
- Bylka W, Znajdek-Awizen P, Studzinska-Sroka E, Brzezinska M. Centella asiatica in cosmetology. Postepy Dermatol Alergol. 2013. PubMed.
- Won JH, Shin JS, Park HJ, et al.. Anti-inflammatory effects of madecassic acid via the suppression of NF-κB pathway. Phytother Res. 2010. PubMed.
Have a question about “Madecassoside: the centella fraction that actually calms angry skin”?
Ask our editorial desk. Best questions become full follow-up articles, reviewed by our medical reviewer. No medical advice given in private — answers run as articles or not at all.